Legend Biotech Corp. ADR (LEGN) News
Filter LEGN News Items
LEGN News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
LEGN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest LEGN News From Around the Web
Below are the latest news stories about LEGEND BIOTECH CORP that investors may wish to consider to help them evaluate LEGN as an investment opportunity.
Top Midday DeclinersDiana Shipping (DSX) has extended the time charter contract for its m/v Amphitrite dry bulk vessel, |
Exploring 3 High Growth Tech Stocks In The United StatesOver the last 7 days, the United States market has experienced a 2.7% drop, yet it remains up by 23% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves focusing on companies that demonstrate strong potential for innovation and adaptability in response to evolving market conditions. |
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceSOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday, January 14, 2025, at 3:45 p.m. PT. Investors and other interested parties can access the live audio webcast through the Investor Relations section of L |
Legend Biotech’s CARVYKTI® Boosts Myeloma Treatment SuccessLegend Biotech (LEGN) has released an update. Legend Biotech’s CARVYKTI® has demonstrated a significant improvement in minimal residual disease negativity for multiple myeloma patients compared to standard treatments, according to recent phase 3 trial results. The study highlights CARVYKTI®’s potential as a transformative cell therapy, achieving an 89% MRD-negative rate in treated patients, which could enhance progression-free and overall survival outcomes. This promising data may bolster invest |
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma89 percent of evaluable patients achieved minimal residual disease (MRD) negativity with CARVYKTI® after three-year follow-up in CARTITUDE-4 study; the majority in less than 2 monthsResults add to the overall survival (OS) benefit recently reported making CARVYKTI® the first and only cell therapy to significantly extend OS versus standard therapies in multiple myelomaLandmark Phase 3 CARTITUDE-4 study data featured as an oral presentation at the 66th American Society of Hematology (ASH) Annual M |
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti. |
Why Is Legend Biotech Corp. (LEGN) Among the Best Up and Coming Stocks to Buy According to Analysts?We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going to take a look at where Legend Biotech Corp. (NASDAQ:LEGN) stands against the other up and coming stocks. Donald Trump’s victory in the recent presidential election is expected to encourage companies that […] |
Legend Biotech Corp. (LEGN): Among the NASDAQ Stocks with Biggest Upside Potential According to AnalystsWe recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we are going to take a look at where Legend Biotech Corp. (NASDAQ:LEGN) stands against the other NASDAQ stocks. Potomac Wealth Advisors president Mark Avallone joined CNBC’s ‘The Exchange’ on November 16 to discuss where he […] |
Why Is Legend Biotech Corporation (LEGN) Among the Worst Performing Biotech Stocks in 2024?We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look at where Legend Biotech Corporation (NASDAQ:LEGN) stands against the other biotech stocks. Biotechnology Stocks: Navigating Volatility Amid Market Fluctuations and Industry Growth Biotechnology stocks are among the most volatile in the market […] |
High Growth Tech Stocks in the United States to WatchOver the last 7 days, the United States market has dropped by 1.0%, but it has experienced a robust growth of 30% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that can capitalize on technological advancements and maintain strong performance despite short-term market fluctuations. |